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Abstract
The laminin receptor (LamR) is a cell surface receptor for extracellular matrix laminin, whereas the same protein within the
cell interacts with ribosomes, nuclear proteins and cytoskeletal fibers. LamR has been shown to be a receptor for several
bacteria and viruses. Furthermore, LamR interacts with both cellular and infectious forms of the prion protein, PrPC and
PrPSc. Indeed, LamR is a receptor for PrPC. Whether LamR interacts with PrPSc exclusively in a capacity of the PrP receptor, or
LamR specifically recognizes prion determinants of PrPSc, is unclear. In order to explore whether LamR has a propensity to
interact with prions and amyloids, we examined LamR interaction with the yeast prion-forming protein, Sup35. Sup35 is a
translation termination factor with no homology or functional relationship to PrP. Plasmids expressing LamR or LamR fused
with the green fluorescent protein (GFP) were transformed into yeast strain variants differing by the presence or absence of
the prion conformation of Sup35, respectively [PSI+] and [psi2]. Analyses by immunoprecipitation, centrifugal fractionation
and fluorescent microscopy reveal interaction between LamR and Sup35 in [PSI+] strains. The presence of [PSI+] promotes
LamR co-precipitation with Sup35 as well as LamR aggregation. In [PSI+] cells, LamR tagged with GFP or mCherry forms
bright fluorescent aggregates that co-localize with visible [PSI+] foci. The yeast prion model will facilitate studying the
interaction of LamR with amyloidogenic prions in a safe and easily manipulated system that may lead to a better
understanding and treatment of amyloid diseases.
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Introduction
The laminin receptor-1 (LamR) is a multifunctional protein
required for cell viability [1,2,3]. Originally isolated by its ability to
bind laminin-1 [4,5,6], LamR has since been identified as a highly
conserved ribosomal protein that has evolved extra-ribosomal
functions in multicellular organisms [7].
As a cell surface receptor, LamR functions in cell migration [8],
through interaction with and remodeling of the extracellular
matrix [9]. In tumor cells these functions have been associated
with increased invasiveness and metastasis [9,10,11,12]. The role
of LamR in cellular translation and proliferation [13] may account
for the upregulation of LamR expression in tumor cells [10,11].
LamR has also been identified as a receptor for bacterial [14,15]
and viral infections [16,17,18,19]. For a review of LamR and
associated pathologies see [20].
The LamR is also a receptor for cellular [21,22] and infectious
[23,24] prion proteins, PrPC and PrPSc, respectively. The LamR
was identified as an interacting partner with the human prion
protein, PrP, in a yeast two-hybrid screen [22]. Function of LamR
as a cell surface receptor for the cellular prion protein, PrPC, has
been shown by co-localization of LamR and PrPC on the surface
of mouse neuronal cells, as well as by the ability of LamR antibody
to block exogenous PrPC cellular binding and subsequent
internalization [21]. Physiological significance of LamR interac-
tion with PrPSc has been demonstrated by the prevention of prion
propagation in neuronal cells by incubation with LamR antibody
or by transfection of LamR antisense RNA and siRNA [25].
Cultures of intestinal enterocytes have been shown to internalize
bovine spongiform encephalopathy prions through binding to cell
surface LamR [24], indicating that LamR may be involved in the
initial stage of prion infections. Similarly, co-localization of LamR
with scrapie and chronic wasting disease prions has also been
demonstrated [23].
PrPSc-associated prion disease belongs to the broader class of
pathologies known as amyloidoses, among which are Alzheimer’s
and Parkinson’s diseases. Prions propagate by conversion of
soluble prionogenic PrPC proteins into the aggregated PrPSc form
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in a concentration- and nucleation-dependent manner, similar to
the process of amyloidosis. Upon conversion to the prion state, the
proteins adopt a cross-beta-sheet-rich structure, typical of amy-
loids. Purified recombinant PrP proteins can polymerize to
amyloid fibers, which are resistant to SDS denaturation and bind
to the amyloid-binding fluorophore thioflavin T and Congo Red
dye [26]. However, the relationship between PrP amyloid forming
in vitro, and known as PrPRes, and prion infectivity is not
completely defined. Infectious PrPSc and recombinant PrPRes
fibrils have been shown to differ structurally and to have different
seeding specificities [27].
Starting from 1994, several prions and prion-like proteins have
been identified in yeast Saccharomyces cerevisiae (reviewed in [28,29]).
While the physiological importance of the ability to form self-
propagating structures is a subject of debate, the occurrence of
prion proteins is evolutionally conserved, and, for several yeast
prions, numerous prion-bearing strains were isolated from nature
[29,30,31]. Prionogenic proteins do not share amino acid
sequence or functional homology. The tendency to form amyloid
structure appears to be dependent upon amino acid composition:
abundance of polar residues and paucity of hydrophobic and
charged residues [31]. Yeast prions show typical amyloidogenic
properties (reviewed in [29,32,33]).
Sup35, a yeast prion-forming protein that has been extensively
studied, is a translational termination factor (eRF3) in its soluble
form [34,35]. However, when aggregated as a prion [36,37],
[PSI+], Sup35 is unavailable to terminate protein synthesis. Under
this condition, protein termination is suppressed as ribosomes
occasionally read through stop codons. Introduction of a stop
codon mutation within a gene encoding the metabolic enzyme,
ADE1 [38], engendered a model system for studying yeast
prionogenesis. The model utilizes the different phenotypes of
prion positive [PSI+] vs prion negative [psi2] strains [39,40]. This
model has already produced many valuable studies into the nature
of prion propagation and amyloidogenesis [31,41,42,43,44].
Furthermore, a yeast [PSI+]-based model was used for drug-
screening: compounds isolated for their ability to affect yeast
prions in this system, have also been demonstrated to be effective
against PrP prions in mammalian cell assays [45].
In this study, we utilize the yeast Sup35/[PSI+] prion model
system to investigate the putative propensity of LamR to interact
with prionogenic proteins by examining the association of LamR
with non-PrP prions. Yeast plasmids expressing LamR were
introduced into Saccromyces cerivceae [PSI+] and [psi2] strains.
Evidence from immunoprecipitation, high-speed centrifugation
assays and fluorescent microscopy reveal an interaction between
LamR and Sup35 in [PSI+] cells, indicating that LamR interacts
with Sup35-based prion protein.
Materials and Methods
Yeast Strains
Yeast strains used are derivatives of 74-D694 (MATa ade1-14
his3- D200 ura3-52 leu2-3, 112 trp1-289) [psi2][PIN+] [39].
[PSI+][PIN+] are strong and weak [PSI+] isolates (L1762 and
L1759, respectively) obtained by overexpression of the Sup35
prion domain [40]. Isolates [psi2][pin2] (L1951) and strong
(L1763) and weak (L1759) [PSI+][pin2] were obtained from
[psi2][PIN+] (L1749), strong [PSI+][PIN+] (L1762) and weak
[PSI+][PIN+] (1758), respectively, by curing [PIN+] upon growing
yeast on media containing 5 mM GuHCl [46,47].
Plasmids and Transformation
The centromeric pRS400 series plasmids are the backbone for
plasmids used in this study [48]. The URA3 pRS416-based
pCUP1-GFP encodes GFP expressed under the control of the
copper inducible CUP1 promoter, and pCUP1-SUP35::GFP
encodes the SUP35 ORF fused to the N-terminus of GFP [49].
These plasmids were a gift from S. Lindquist to I. Derkatch.
PCR fragments, synthesized from a human LamR expression
vector [50], were generated to construct pCUP1-LamR and
pCUP1-LamR::GFP; 59 primer: BamHI GGATCCATGTCCG-
GAGCCCTTGATGTCC; 39 primers: SacII CCGCGGTTAA-
GACCAGTCAGTGGTTGCTCC with a stop codon at the end
of the LamR ORF, and SacII CCGCGGAGACCAGT-
CAGTGGTTGCTCCTAC for LamR::GFP. Fragments were
inserted into the pCUP1-GFP plasmid (see above).
To co-express the URA3 pCUP1-SUP35::GFP with wild type or
mCherry-tagged LamR, an XhoI/SacII fragment, containing the
CUP1 promoter and LAMR, was excised, from either the pRS416-
pCUP1-LamR or the pRS416-pCUP1-LamR::GFP construct,
and subcloned into the LEU plasmid, pRS415, to confer selective
growth in leucineless medium. An mCherry-encoding PCR
fragment was synthesized from a pmCherry vector (Clonetech,
#632522) using primers: 59 Primer: SacII CCGCGGATGGTGAG-
CAAGGGC; 39 primer SacII CCGCGGCTACAGCTCGTC-
CATGC. The SacII/SacII mCherry fragment was cloned into
the SacII site of the construct with the CUP1-LAMR insert
originating from pRS416-pCUP-LamR::GFP, to generate a
LamR::mCherry fusion protein.
Standard yeast media and procedures were used [51]. Yeast
transformants were grown in synthetic dextrose media selective for
plasmid maintenance: SD-Ura, SD-Leu, or SD-Ura-Leu [51]. To
induce the CUP1 promoter, media were supplemented with
25 mM CuSO4.
Yeast Lysates
Yeast cell lysates were prepared from mid-log cultures grown
overnight at 30uC in plasmid-selective media supplemented with
25 mM CuSO4 (unless stated otherwise). Cells were harvested by
centrifugation at 8006g for 10 min and washed with distilled H2O
at RT. Pellets were resuspended in 26volume lysis buffer [50 mM
TrisHCl pH 7.5, 250 mM NaCl, 10 mM MgCl2, 5% w/v
glycerol, anti-protease cocktail for yeast (Sigma) and 0.1 M
AEBSF (Sigma)] and disrupted by beating with an equal volume
of acid washed glass beads (425–600 mm, Sigma) [10 pulses of
vortexing for 30 secs each, placing tubes on ice between vortexing
to avoid heating]. Cell disruption was monitored microscopically.
Lysates were pre-cleared at 8006g for 10 min.
Western Blot Analysis and Antibodies
Protein concentrations were measured using BioRad Dc Protein
Reagent. Proteins were separated on 4–15% gradient SDS-
polyacrylamide gels (BioRad) under reducing conditions. Proteins
were transferred to polyvinylidene fluoride membrane (Millipore)
in Tris-glycine buffer pH 7.5 containing 10% methanol. Filters
were blocked at RT in 5% non-fat dry milk in TBST [0.1 M
TrisHCl pH 7.5, 0.15 M NaCl, and 0.1% Tween-20 (Sigma)].
Incubation with primary antibodies was overnight at 4uC. After
TBST wash (465 min), appropriate secondary HRP-conjugated
antibodies were applied for 90 min at RT. Filters were washed, as
above, then developed with ECL (Pierce) and exposed to Highblot
CL autoradiography film. Films were scanned using an Epson
V600 scanner. Densitometry was performed using NIH ImageJ
1.44f software [http://rsb.info.nih.gov/ij].
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Antibodies used were: anti-LamR 1:1000 (H-2, mouse mAb,
74515 Santa Cruz) in 5% milk; anti-Sup35 1:1000 in PBS (BE4
mouse mAb, [52], a gift from Susan Liebman to ILD); anti-GFP
1:1000 (Invitrogen rabbit pAb, A11122) in 5% milk; anti-yeast
hexokinase-HRP 1:1000 (Abcam, ab34588) in 5% milk.
Coimmunoprecipitation
Immunoprecipitation was performed using magnetic, Protein
G, Dynabeads (Dynal, Invitrogen) according to manufacturer’s
protocol. Anti-GFP antibody (10 mg) was adsorbed to 50 ml bead
slurry. Control beads were prepared with 10 mg rabbit IgG. Yeast
cell lysates (500 mg in 200 ml lysis buffer) were added to prepared
antibody-bound beads and rotated overnight at 4uC. Beads were
removed magnetically, and supernatant removed as unbound (flow
thru, FT) fraction. Beads were washed with 500 ml PBS with
0.02% Tween-20 (PBST), transferred to a new tube with PBST
and washed an additional 26. One ml TBST was added to
separated beads. Beads were transferred to a new tube and washed
36 in TBST. Bound protein was removed by incubation of
separated beads at 70uC, 10 min in 16SDS PAGE buffer (50 ml).
Eluted protein (25 ml) and 20 mg total cell lysate and FT fraction
were separated on SDS PAGE gels and analyzed by western blot.
Fluorescence Microscopy
Cultures of yeast transformants, grown at 30uC in plasmid
selective media supplemented with 25 mM CuSO4 from 0.02 OD
600 nm to late-log (48 hours) were viewed with the Plan Fluor
100x/1.3 oil DIC lens of a Nikon TE-2000E fluorescent
microscope using a 488 nmex, 507 nmem filter for GFP and a
589 nmex 615 nmem filter for mCherry. Images were captured
with a Nikon CoolSnap EZ camera and processed with NIS
Elements V2.3 software.
High Speed Centrifugation Analysis
Lysates for centrifugation assays [36] were prepared as
described above except that RNAse A (400 mg/ml) was added to
yeast lysate buffer to disrupt ribosomes and lysates were precleared
at 80006g, 3 min [53]. Approximately 200 ml lysate was spun,
30 min, at 100,0006g in a Beckman TLA 120.1 rotor (Beckman
Optima TLX ultracentrifuge). Supernatants were carefully
removed and pellets resuspended in equal volume (200 ml) of lysis
buffer. Equal amounts (20 mg) of total, supernatant and pellet
protein were analyzed by western blot.
Results
Expression of Human LamR in Yeast Cell
The human LamR was expressed under the control of the
copper inducible CUP1 promoter from a low-copy yeast plasmid.
Both untagged and C-terminal GFP fusion constructs were made.
The size of the expressed proteins was as expected, ,37 and
64 kDa, respectively, and expression levels were similar for the
untagged LamR and the GFP LamR fusion proteins (Fig. 1A, right
panel and left panel, respectively). The GFP fusion construct was
utilized to enable intracellular visualization of LamR and provide
an epitope for immunoprecipitation.
Figure 1A (left panel) shows that the CUP1 promoter induction,
in the presence of 25 mM CuSO4, enhanced expression of the
64 kDa LamR-GFP fusion protein compared to basal level
expression observed in the cells grown in media with no excess
CuSO4. The right panel shows expression of the untagged LamR
grown in the presence of 25 mM CuSO4. While the mouse
monoclonal LamR antibody H-2, raised against a polypeptide
including amino acids 110–150 of the LamR, was able to
recognize the human LamR protein in yeast cell lysates, the
antibody does not react with any endogenous protein in the yeast
extract. Specifically, an expected 30 kDa band for the orthologous
RPS0 yeast ribosomal protein is not observed on western blots
(Fig. 1A). Moreover, extract from untransformed yeast cells
showed no reacting protein bands (not shown). Apparently, the
epitope recognized by the LamR H-2 antibody is absent in RPS0
or is not strongly reactive with the H2 antibody.
When plasmids expressing GFP, LamR-GFP or Sup35-GFP,
were transformed into yeast strains that either lacked or contained
the [PSI+] prion, the GFP, LamR-GFP and Sup35-GFP proteins
Figure 1. Human LamR is expressed in yeast cells. A. LamR
protein (right panel) or LamR-GFP fusion (left panel) expressed in the
[PSI+][PIN+] yeast prion strain grown in synthetic media either
supplemented with 25 mM CuSO4 (right panel and lane 2 of left panel)
or containing no excess copper (lane1 of left panel). B. Expression of
GPF (27 kDa), and LamR-GFP and Sup35-GFP fusion proteins (64 kDa
and 104 kDa, respectively) in [psi2][PIN+] (2) and [PSI+][PIN+] (+) yeast
strains. Anti-LamR (A) and anti-GFP (B) antibodies were used to detect
LamR expression in yeast lysates (25 ug). Numbers in the middle (A) and
right (B) refer to protein size markers (kDa). Similar expression levels
were observed in [pin2] strains (not shown).
doi:10.1371/journal.pone.0086013.g001
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were expressed at relatively equivalent levels in [psi2][PIN+] and
[PSI+][PIN+] yeast strains (Fig. 1B).
LamR Interacts with Yeast Sup35 Protein
To assess the interaction of the human LamR with yeast Sup35
monomers or Sup35 prion aggregates/oligomers, co-immunopre-
cipitation experiments were performed. Lysates of CuSO4-induced
cells were incubated with protein G-linked magnetic beads bound
with GFP antibody. Figure 2 shows western blots of GFP
antibody-precipitated lysate samples that were probed with
antibody to Sup35 (A) or LamR (B). In lysates expressing
LamR-GFP (Fig. 2A, panels 2 and 4), 76 kDa Sup35 protein
bands appear in the eluted fractions of both [psi2] and [PSI+] yeast
strains, but the relative amount of pulled-down Sup35 is
significantly higher in the [PSI+] lysates. Lysate fractions eluted
from yeast that expressed only GFP protein did not show a 76 kDa
Sup35 protein band indicating a specific interaction between the
LamR and Sup35 proteins (Fig. 2A, panels 1 and 3). Also, control
beads bound with mouse IgG did not bind Sup35 (not shown).
Although a significantly lesser amount of Sup35 eluted from
LamR beads in the [psi2] strain, the elution of small amounts of
Sup35, as opposed to complete absence of Sup35 in eluates, may
be due to an interaction of LamR with the monomeric Sup35, or
due to the presence of insignificant amounts non-heritable Sup35
oligomers. Indeed, some amounts of aggregated Sup35 are always
detected in centrifugation assays in [psi2] strains (see Fig. 3).
Co-expression of wild type LamR with GFP or Sup35-GFP
showed similar results (Fig. 2B). Expression of LamR with GFP
protein alone did not result in the elution of a 37 kDa LamR band
from anti-GFP coated beads in either [psi2] or [PSI+] yeast lysates
(panels 1 and 3). In [psi2] yeast co-expressing LamR with Sup35-
GFP very small amounts of 37 kDa LamR were observed in anti-
GFP eluates, but a very strong band specifically recognized by
anti-LamR appeared at approximately 100 kDa. [PSI+] yeast
lysates co-expressing LamR with Sup35-GFP contained signifi-
cantly higher amounts of 37 kDa LamR (Fig. 2B) and even greater
amounts of higher molecular weight bands were also observed.
Filters, completely stripped of LamR antibody, and reprobed with
Sup35 antibody showed coincident higher molecular weight bands
(not shown).
The co-immunoprecipitation experiments reveal an interaction
between LamR and Sup35, the exact nature of which is not yet
clear. Associations may occur between monomeric proteins,
oligomers or aggregates. Presence of Sup35 and LamR together
in higher molecular weight bands may be caused by anomalous
migration of proteins in SDS PAGE gel due to aggregation.
Figure 2. Human LamR co-immunoprecipitates with yeast Sup35 protein. Yeast cell lysates (500 ug) from transformants of [psi2][PIN+] and
[PSI+][PIN+] strains carrying (A) pCUP1-GFP or pCUP1-LamR::GFP and (B) wild type pCUP1-LamR together with either pCUP-GFP or pCUP-SUP35::GFP
were precipitated with anti-GFP antibody. Total eluted proteins (E) were compared with 20 ug cell lysate (CL) and unbound (flow thru, FT) samples;
eluted samples represent 126the amount of CL and FT. Western blots were probed with anti-Sup35 antibody (A) or anti-LamR antibody (B). Numbers
on the right (A and B) refer to protein size markers (kDa). High molecular weight LamR bands are observed from 60–100 k Da in the presence of
Sup35-GFP (B, panels 2 and 4). The 50 kDa and 25 kDa bands in A and B are the heavy and light chain IgG bands, respectively. Shown are
representative experiments; similar results have been obtained for at least three independent experiments.
doi:10.1371/journal.pone.0086013.g002
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Co-distribution of LamR with Sup35 Prion Protein
Centrifugation analysis provides another method to examine the
aggregation of LamR in the presence of the Sup35-based prion.
High-speed centrifugation sediments prion aggregates whereas
non-aggregated forms of the proteins tend to remain in the
supernatant [36]. Total yeast cell lysates, 100,0006g pellets and
soluble supernatant fractions were analyzed by western blot. In
this experiment, both pCUP1-LamR::GFP and pCUP1-LamR
transformants were used, and supernatant and pellet fractions
were probed for the exogenous human LamR and the endogenous
Sup35 proteins. To ensure that unbroken cells or supernatant
lysate did not contaminate the pellet fractions, membranes were
probed with antibody to yeast hexokinase 1, which is located only
in the cytoplasm (Fig. 3A).
In [PSI+] cell lysates, whether LamR or LamR-GFP was
expressed, almost all Sup35 and .40% of LamR were detected in
the pellet fraction, indicative of their aggregated state. Conversely,
in [psi2] cells, the distribution of both Sup35 and LamR was
shifted towards the soluble fraction. The ratio of aggregated LamR
to soluble LamR was reversed, with the vast majority of LamR
detected in the supernatant (,80%). This further indicates that
LamR becomes insoluble in the presence of the [PSI+] prions.
To further exclude the possibility that GFP contributed to
LamR aggregation, analysis of pCUP1-GFP transformants showed
that the GFP protein did not produce aggregates regardless of the
presence of [PSI+] (Fig. 3A and not shown).
In summary, detection of LamR in the high-speed centrifugal
pellets of the [PSI+] lysates supports an association of LamR with
aggregated Sup35 protein.
LamR-GFP Forms Fluorescent Foci in [PSI+] Yeast Strains
As the co-immunoprecipitation and co-distribution experiments
indicated the [PSI+] prion-dependent interaction of LamR and
Sup35, we examined whether, like Sup35, LamR forms visible
cytoplasmic aggregates in yeast cells. The distribution of GFP,
LamR-GFP and Sup35-GFP was examined in [PSI+] and [psi2]
cells. Figure 4A displays representative images of yeast cells from
two independent transformants of the [PSI+] strain. As expected,
yeast cells expressing GFP showed relatively even, diffuse,
cytoplasmic distribution of fluorescence. Also, as shown before
[36], in [PSI+] cells that expressed Sup35-GFP, Sup35 was
Figure 3. Centrifugation assay demonstrates aggregation of exogenous human LamR in the presence of the [PSI+] prion. (A) Total
lysate (T), supernatant (S), and resuspended pellet (P) (20 mg per sample) of pCUP1-LamR::GFP and pCUP1-LamR transformants of yeast [psi2][pin2]
and [PSI+][PIN+] strains were analyzed by western blot using the indicated antibodies. pCUP1-GFP was expressed in the [PSI+] strain as a control
(bottom panel), and anti-yeast hexokinase antibody (anti-HK) was used to ensure pellets were free of cytoplasmic proteins (fifth panel from top).
Shown are representative experiments out of 3 independent experiments. (B) Corresponding densitometric quantitation of percent distribution
between supernatant and pellet fractions was determined from three independent experiments. Bars show standard error of the mean.
doi:10.1371/journal.pone.0086013.g003
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detected predominantly in bright fluorescent foci with hardly any
protein visible in the cytoplasm. The expression pattern of LamR-
GFP strikingly resembled that of Sup35: in most cells LamR was
seen in bright foci with very little non-aggregated protein.
In [psi2][PIN+] cells (Fig. 4 B) both Sup35 and LamR-GFP were
usually distributed evenly in the cytoplasm. However, in some cells
both Sup35-GFP and LamR formed [PSI+] like aggregates. The
formation of [PSI+] aggregates following overexpression of the
Figure 4. Immunofluorescence of LamR-GFP and Sup35-GFP fusion proteins reveals aggregation of LamR in [PSI+] cells. Late-log
cultures of (A) [PSI+][PIN+], (B) [PSI+][pin2], (C) [psi2][PIN+] and (D) [psi2 ][pin2] were examined with 1006 oil immersion lens of a fluorescent
microscope using a 488ex, 507em filter. Representative images from two independent transformants of each yeast strain are displayed.
doi:10.1371/journal.pone.0086013.g004
LamR Interaction with Yeast Sup35/[PSI+] Protein
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Sup35-GFP construct was expected because the strain used in this
experiment carries another prion, [PIN+]. The presence of the
[PIN+] prion, which is a self-propagating state of the Rnq1 protein
[46,47,54,55], allows for the de novo [PSI+] formation upon
overexpression of the Sup35 protein [46,47,54], apparently due
to the direct seeding of the [PSI+] prion by the pre-existing [PIN+]
prion aggregates [54,56,57,58]. The LamR aggregates in these
[psi2][PIN+] cells could result from either co-aggregating with the
newly forming [PSI+] or from interaction of LamR with [PIN+].
To distinguish between these possibilities, we employed [pin2]
variants of the same strains, [PSI+][pin–] (Fig. 4C) and [psi2][pin2]
(Fig. 4D). In [PSI+][pin–] transformants, aggregation patterns of all
proteins, GFP, Sup35-GFP and LamR-GFP were indistinguish-
able from [PSI+][PIN+] indicating that [PIN+] did not determine
the LamR aggregation (Fig. 4C). In [psi2][pin2] cells both Sup35
and LamR-GFP were evenly distributed in the cytoplasm (Fig. 4D).
As new [PSI+] formation does not occur when Sup35 is
overproduced in the absence of [PIN+] [47], the fact that LamR-
GFP was also non-clustered in [pin2][psi2] cells strongly indicates
that LamR aggregation in [PSI+][PIN+] (Fig. 4A) and [PSI+][pin2]
cells (Fig. 4C) was driven by the [PSI+I] prion, and suggest that
LamR binds to the pre-existing and newly forming [PSI+] prion.
Sup35-GFP and LamR-mCherry Co-localize with [PSI+] or
Newly Forming [PSI+]
Analysis of fluorescent aggregates in cells co-expressing Sup35-
GFP and LamR-mCherry clearly reveals the [PSI+]-dependent
interaction between the Sup35 and LamR proteins. Overlapping
Sup35 and LamR punctate foci were observed in cells of the weak
[PSI+][pin 2] strain transformed with pCUP1-SUP35::GFP and
pCUP1-LamR::mCherry (Figure 5, two top rows, A and B refer to
two independent transformants). Sup35 and LamR foci could also
be found in strong prion yeast cells, however, the cytotoxicity
associated with over-expression of Sup35 (pCUP1-SUP35::GFP)
in the strong [PSI+] strains [59] made it difficult to detect and
image aggregate-containing cells (not shown). Also, as expected, if
the presence of LamR foci were coupled with the [PSI+] prion, and
consistent with observations described in Figure 4D, fluorescently-
labeled Sup35 and LamR were evenly dispersed throughout the
cytoplasm of [psi2][pin2] yeast transformants (not shown).
We also followed localization of LamR and Sup35 in
[psi–][PIN+] cells where the [PSI+] prion is forming de novo (see
Figure 4B above). The newly generated prions can take the form of
punctate dots, ring-like or branched ring structures [49]. The two
bottom panels of Figure 5 show cell clusters from two independent
[psi–][PIN+] transformants. The first cluster (A) contains dot
aggregates for Sup35, indicative of heritable [PSI+], and the
second cluster – a branched ring (B), which is a non-mature form
of [PSI+]. In both cases Sup35 aggregates co-localize with LamR-
mCherry visible aggregates. These results suggest that LamR may
interact with different prion-like conformers of Sup35. Co-
localization is observed in both mother and daughter cells,
indicative of a heritable transmission of LamR with [PSI+],
although re-association cannot be excluded by these experiments.
LamR-GFP Expression does not Change the [PSI] Status of
Yeast Cells
Previous experimental evidence shows that interactions of
prion-forming proteins with various cellular proteins may result
in either de novo appearance or loss of pre-existing prions; this is
true for both interactions between two different prion forming
proteins (reviewed in [60]), and between prion-forming proteins
and proteins that are not amyloidogenic themselves. Such non-
amyloidogenic proteins include various chaperones (reviewed in
[61]) or overexpressed interacting partners of prion-forming
proteins, like Sup45, which forms a translation termination
complex with soluble Sup35 [61,62]. We tested if LamR
expression can cure [PSI+] in [PSI+] strains or promote [PSI+]
formation in [psi2] cells. Using standard genetic assays to examine
the propagation or loss of Sup35 prions [63,64,65], no effect was
observed when pCUP1-LamR or pCUP1-LamR::GFP were
expressed in [PSI+][PIN+], [psi2][pin2], [PSI+][pin2] or [psi2][-
PIN+] yeast strains for over 30 replicative generations (not shown).
Discussion
The data presented show an in vivo interaction between LamR
and Sup35 protein when Sup35 is present in the prion [PSI+] state.
1) In co-immunoprecipitation assays, Sup35 protein is pulled down
with LamR-GFP from yeast cell lysates and, conversely, LamR is
pulled down with Sup35-GFP). 2) In centrifugation assays, in
[PSI+] cell lysates, LamR was shifted to pellet fractions together
with insoluble Sup35 protein. 3) Aggregation patterns of LamR
and Sup35 were strikingly similar, with LamR-GFP forming
punctate fluorescent foci in [PSI+] cells and in cultures where
[PSI+] formation is possible. Furthermore, visible LamR-mCherry
co-localized with both pre-existing and newly forming [PSI+].
Although the nature of the interaction between LamR and Sup35
prion protein has not been elucidated, the results indicate the
adherence of LamR to [PSI+] prion aggregates, as opposed to,
interference or enhancement of the amyloidogenic process.
As part of the protein translation machinery, the yeast and
human orthologs of LamR and Sup35, respectively, are highly
homologous. The homology, however, is not universally strong
throughout the proteins. For both Sup35 and LamR there is an
ancient, highly conserved part of the protein and a more recently
acquired variable extension. For example, the yeast ortholog of
LamR, RPS0, has 252 amino acid residues compared with LamR
(RPSA), which contains 295 residues. The additional amino acid
residues of mammalian RPSA comprise a C-terminal domain that
is thought to have evolved with the gain of the laminin binding
function as organisms became multicellular [7]. Likewise, yeast
Sup35 (eRF3) is a member of a protein family including ancient
EF-Tu/eEF1A elongation factors [35]. The Sup35 region that is
homologous with EF-Tu/eEF1A encompasses the GTP- and
aminoacyl-tRNA-binding sites, is highly conserved and sufficient
for viability and translation termination; respective regions of yeast
and human proteins are 57% identical and 75% similar. On the
other hand, the ,200 amino acid long N-terminal extension,
present only in Sup35/eRF3 proteins, is more variable. The exact
role of this N-terminal extension is not known. In yeast it
encompasses the Q/N-rich amyloidogenic region at the extreme
N-terminus, which is essential for [PSI+] formation and mainte-
nance [35,40,66]. While mammalian eRF factors lack the Q/N-
rich region, other segments of their N-terminal extension share
similar amino acid composition with Sup35/eRF3, suggesting the
possibility of functional conservation.
Although interaction of LamR (RPSA) and Sup35 as parts of
the ribosomal complex is an obvious hypothesis, our results do not
support an interaction that is dependent exclusively upon their
ribosomal functions. Indeed, in this case, the interaction is
expected to be as efficient when Sup35 is in a soluble non-prion
state, whereas, our data suggest that interaction is facilitated by the
aggregated protein. In addition, the fact that human eRF3
proteins have not been found to be in complex with LamR in a
stringent proteomic study of human LamR binding proteins
indicates that interaction does not occur within the framework of a
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major and constitutive cellular process involving a considerable
fraction of each protein [67].
Our data indicate, rather, that interaction between LamR and
Sup35 is directed by their newly gained functions, implicating
their more recently acquired domains. Acquisition of an extended
C-terminus by LamR is thought to be important for the cell
surface localization of LamR, its external position allowing for
extracellular interactions [7,20]. The importance of this functional
role is reflected by the very high degree of conservation in
vertebrates throughout the entire LamR protein sequence [7].
Positioned externally, the LamR C-terminus can bind with
laminin and serve as a receptor for various molecules, including
PrPC and PrPSc, as cited in the introduction.
The ability of LamR to bind PrPSc [23,24] has led us to
hypothesize that the LamR may have an affinity for structures
characteristic of prions and amyloidogenic proteins. Indeed, while
there is no evidence that formation of laminin-1, first used to
isolate LamR, involves typical amyloid, it contains a fibrous,
coiled-coil, a-helical domain that forms a network in the
extracellular matrix [68,69]. Furthermore, amyloidogenic se-
quences have been identified in laminin-1. Peptides of these
sequences form amyloid fibers in vitro and can presumably form
in vivo when laminin-1 is fragmented or unstructured while
undergoing conformational transformations [70]. Analysis indi-
cates that the extracellular C-terminal domain of LamR is a
disordered structure [71]. It is increasingly apparent that
Figure 5. LamR co-localizes with visible Sup35 prion aggregates in yeast cells. pSUP35-GFP and pLamR-mCherry were co-expressed in
weak [PSI+][pin2] and [psi2][PIN+] cells. Panels show GFP and mCherry fluorescence and their merged images. Brightfield (BF) images of the cells are
shown in the far right panel. Two sets of images (A and B) are shown from independent transformants. Images were taken using a1006oil immersion
lens. The images were visualized and merged using Adobe photoshop CS4.
doi:10.1371/journal.pone.0086013.g005
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disordered domains are common among proteins that form
multiple protein-protein interactions [72,73], and may be both
involved with specific binding or engage in protein-protein
contacts in a less specific manner. Different regions or conforma-
tions of the LamR protein may modulate its interaction with
human PrPC vs PrPSc. While specific binding sites have been
identified, on each protein, for interaction between LamR and
PrPC [22], LamR binding with PrPSc has not been defined.
Significant experimental evidence suggests that both LamR and
Sup35-based prions are associated with the actin cytoskeleton, and
thus it is plausible that the actin cytoskeleton can mediate LamR
and Sup35/[PSI+] interaction. Components of the actin cortical
cytoskeleton have been shown to interact with the prion domain of
Sup35. This association promotes de novo [PSI+] prion formation
and aggregation [74]. LamR has also been shown to interact with
the cytoskeletal network within mammalian cells [8,75,76,77,78].
Specifically, co-localization has been shown with actin filaments
in vivo [8,78] and in vitro [78] and interaction with microfilaments
is important for cell adhesion and motility. Ganusova et al. have
proposed a model whereby the yeast actin cytoskeleton acts as a
scaffold for the amyloid-based aggregation of misfolded proteins,
reducing the toxicity of misfolded proteins by sequestration from
the cytosol [74]. The cytoskeleton may also serve as a location for
protein refolding. Chaperone proteins that contribute to [PSI+]
propagation [61,74] have been found at the cytoskeleton [74]. In
this regard, it is noteworthy that LamR amino acid residues 1–120
share some homology with the Hsp70 chaperone protein [79].
In conclusion, our findings reveal the propensity of LamR to
interact with different prion-forming proteins and raise the
possibility that LamR interaction with mammalian prion protein
occurs not only in the capacity of the PrPC receptor, but is
implicated in either prion infectivity or prevention of prion
infection through a structural affinity for PrPSc. Utilization of the
yeast assay system provides a safe and easily manipulated system
for further study of LamR binding to prions and amyloids.
Structure guided mutagenesis has been used to delineate the
laminin-1 binding site of LamR [80]. Similarly, mutagenesis
experiments can be designed to probe the interaction of LamR
with Sup35 and other amyloid-like proteins. It is hoped that such
studies will facilitate an understanding of the multifunctional
interactions of the LamR protein.
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